CION Ameerpet
Immunotherapy · Liver, Colorectal & Lower GI Cancer
Immunotherapy With Hepatitis B or Cirrhosis — What Screening Comes First
Hepatitis B or cirrhosis does not automatically rule you out of immunotherapy, and it does not qualify you either. Eligibility turns on your cancer type, your biomarker result and how well your liver is still working. Screening for hepatitis B and C before treatment is standing protocol for every patient, not a comment on your history.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- Most patients are not candidates — for liver and lower GI cancers, immunotherapy applies to a minority. Your biomarker result and liver function decide it, not the hepatitis status.
- Hepatitis B is not an automatic bar — with the virus suppressed by antiviral tablets and liver function preserved, treatment can usually go ahead with closer monitoring.
- Reactivation is planned for, not hoped against — antiviral cover is started before the first cycle wherever the screening result calls for it, in line with ASCO and NCCN guidance.
- Decompensated cirrhosis changes the answer — Child-Pugh C, and Class B beyond the early range, is where most teams stop, because the liver has little reserve left.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
The short answer
Is Immunotherapy Safe If You Have Hepatitis B or Cirrhosis?
Most patients with liver or lower-GI cancer in India are not candidates for immunotherapy at all. Among those who are, chronic hepatitis B or well-compensated cirrhosis is usually not a bar. The virus is suppressed first and the liver is watched closely. Decompensated cirrhosis is where most teams stop.
That order matters. Eligibility is settled before safety is. In colorectal and lower GI cancer, checkpoint inhibitor immunotherapy is an evidence-based option only when the tumour is MSI-High, also reported as dMMR. That is roughly 15 in every 100 colorectal cancers across all stages, and only about 4 to 5 in every 100 metastatic ones. These proportions follow NCCN and ESMO patient guidance current as of August 2026. For tumours reported as MSS or pMMR, checkpoint inhibitor immunotherapy alone is not an evidence-based treatment, whatever the hepatitis status.
In liver cancer the gate is different. Immunotherapy is used in advanced disease, and only where liver function is still preserved. So a patient with hepatitis B and cirrhosis may be ruled out by the state of the liver rather than by the virus.
Why hepatitis is asked about at all. It is not because it changes whether the cancer will respond. It is because immunotherapy modulates the immune system, and because immune-related side effects are sometimes treated with steroids. Both can let a quiet hepatitis B infection wake up. Knowing your status in advance turns that into something planned for rather than reacted to.
Eligibility and safety are confirmed by a medical oncologist reading your own reports alongside a hepatologist, not by this page. If you have not been told your hepatitis B result or your liver function grade, those are the two things to ask for first.
Reading your liver grade
What Does Child-Pugh A, B or C Mean for This Decision?
Child-Pugh grades how much working liver you still have. It is scored from five things: bilirubin, albumin, clotting time, fluid in the abdomen and confusion. Class A means the liver is compensated. Class C means it is failing.
| Child-Pugh class | Score | What it describes | What it usually means for immunotherapy |
|---|---|---|---|
| Class A | 5 to 6 points | Compensated cirrhosis. No fluid in the abdomen, no confusion, near-normal bilirubin and albumin | Considered, where the cancer indication itself applies. Almost all the published evidence comes from this group |
| Class B | 7 to 9 points | Partly decompensated. Mild fluid in the abdomen, rising bilirubin, falling albumin, prolonged clotting | Case by case, early Class B only, with hepatology co-review. Most trial evidence excludes this group, so any decision is made outside settled evidence and should be explained as such |
| Class C | 10 to 15 points | Decompensated. Marked jaundice, resistant fluid in the abdomen, confusion, severely impaired clotting | Not usually offered. There is too little liver reserve to absorb an immune-related reaction. Liver-directed and supportive care take priority |
Child-Pugh is not the only input. Performance status, portal pressure, previous variceal bleeding and how the cirrhosis has behaved over the past year all weigh in. Some teams also record an ALBI grade, which uses albumin and bilirubin alone and is less dependent on judgement calls about fluid and confusion.
If you have cirrhosis and no one has told you your Child-Pugh class, ask. It is calculated from tests you have almost certainly already had, and it shapes this decision more than any other single number.
Did you know?
WHO estimates that around 3 in every 100 people in India live with chronic hepatitis B, and the large majority have never been tested. That is precisely why hepatitis B and C screening before immunotherapy is standing protocol for every patient at every centre. It is not a question asked because of anything in your history, and a positive result is far more often a surprise than a confirmation.
The risk, plainly
What Is the Hepatitis B Reactivation Risk?
Reactivation means a quiet hepatitis B infection becoming active again. With checkpoint inhibitor immunotherapy alone it is reported as uncommon. The larger risk arrives later, from the steroids sometimes needed to treat an immune-related side effect. Both risks are handled the same way: know the status first, cover with antivirals where indicated.
Who carries the higher risk. Patients who are HBsAg positive, meaning the infection is still present, carry the greater risk. Patients who are anti-HBc positive but HBsAg negative, meaning a past infection the body cleared, carry a lower but genuine risk. ASCO and NCCN guidance current as of August 2026 advise screening every patient before anticancer treatment, and starting antiviral cover where the result calls for it.
What cover looks like. Antiviral tablets are started before or alongside the first cycle and continued for a defined period after treatment ends. The viral load is rechecked on a schedule. Nothing about this is experimental. It is the same protocol used before chemotherapy and before long courses of steroids for any reason.
What is watched at every cycle. Liver enzymes, bilirubin and, where hepatitis B is present, the viral load. A rise is investigated rather than assumed to be one cause or the other, because immune-related hepatitis and a hepatitis B flare are treated in opposite directions.
Do not manage new liver symptoms at home. Yellowing of the eyes or skin, dark urine, pale stools, new confusion or drowsiness, or pain under the right ribs are reasons to contact the treating team the same day rather than waiting for the next cycle. If you cannot reach your team, call 1800 202 8726. If there is confusion, drowsiness or vomiting of blood, go to the nearest emergency department now.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Settle the Hepatitis and Liver Questions Before Treatment Is Planned
A medical oncologist will go through your hepatitis status, your Child-Pugh grade and your pathology report, and set out the realistic options either way. Free, confidential, with no commitment to start treatment.
Before the first cycle
What Screening Comes First?
Every step below is routine protocol before immunotherapy, run for all patients regardless of history. None of it is optional, and none of it is a comment on how anyone thinks you acquired an infection.
1
The hepatitis B panel
Three tests together: HBsAg, which shows current infection; anti-HBc, which shows the body has met the virus at some point; and anti-HBs, which shows immunity from vaccination or from clearing an old infection. All three are needed, because HBsAg alone misses a resolved infection that can still reactivate.
2
Hepatitis C antibody
Taken at the same time. If the antibody is positive, an HCV RNA test follows to show whether the infection is still active or was cleared. Hepatitis C is treatable, and where it is active the hepatology team decides whether to treat it before, during or after cancer treatment.
3
HBV DNA viral load, if any marker is positive
This is the number that later tells an immune-related liver reaction apart from a hepatitis B flare. Having a baseline before the first cycle is what makes a later rise interpretable. Without one, a raised enzyme reading months from now is far harder to explain.
4
Liver function and the degree of scarring
Bilirubin, albumin and INR, plus an assessment of fluid in the abdomen and of confusion, together give the Child-Pugh class described above. Ultrasound or CT shows the liver texture and portal circulation. Liver stiffness measurement is sometimes added where the picture is unclear.
5
Baseline organ-function and autoimmune bloods
Thyroid function, kidney function, blood counts and liver enzymes are recorded before treatment starts. Later changes can then be recognised as immune-related effects rather than guessed at. Where there is any history of autoimmune disease, that is documented here too, because it changes the monitoring plan.
6
Hepatology co-review, tumour board, then day care
Where hepatitis B or cirrhosis is present, a hepatologist reviews the plan alongside the tumour board rather than after it. Antiviral cover is started before the first cycle where the screening result calls for it. Immunotherapy itself is administered as day care at CION centres, so an overnight stay is not usually needed. Response-assessment PET-CT is coordinated at partner imaging centres rather than performed in-house.
Telling them apart
Immune Hepatitis or a Hepatitis B Flare — How Do You Tell?
Both raise liver enzymes. Both can make you tired, darken the urine and yellow the eyes. The symptoms do not separate them. The viral load does, and the two are treated in opposite directions, so the distinction is not academic.
| Immune-related hepatitis | Hepatitis B reactivation flare | |
|---|---|---|
| Typically starts | Most often 6 to 12 weeks after the first infusion, following the onset patterns described in ASCO and ESMO immune-related adverse event guidance. It can appear at any point, including after treatment ends | Any time once immune suppression begins, and often several weeks after steroids are started for another immune-related side effect |
| What you notice | Often nothing at first. It is usually picked up on routine bloods. Later: tiredness, poor appetite, discomfort under the right ribs | Often indistinguishable without tests. Tiredness, dark urine, yellowing of the eyes, sometimes nausea |
| What the bloods show | Rising ALT and AST, sometimes bilirubin, with HBV DNA staying undetectable | Rising ALT and AST alongside a rising HBV DNA viral load |
| What settles it | Viral serology and HBV DNA, compared against your baseline. Occasionally imaging or a liver biopsy | The rise in HBV DNA against baseline is the giveaway |
| Who leads treatment | Medical oncology, with hepatology input. Immunotherapy is usually held while it is assessed | Hepatology, with antiviral treatment started or intensified |
| What you should do | The same in both cases. Report new tiredness, dark urine, pale stools or yellow eyes to the treating team the same day. Do not wait for the next cycle and do not treat it at home. | |
This is also why the baseline matters more than any single later reading. A viral load taken before the first cycle turns an ambiguous result three months from now into a clear one.
Where the answer is no
Who Is Not a Candidate, and Why
These are the situations in which a team will decline immunotherapy, or defer it. Each has a specific, checkable reason. You are entitled to be told which one applies to you, in writing.
- Decompensated cirrhosis — Child-Pugh C, and Class B beyond the early range. There is too little liver reserve to absorb an immune-related reaction, and the published evidence was generated almost entirely in Class A patients.
- Active, unsuppressed hepatitis B — this defers treatment rather than cancels it. Antiviral tablets are started, the viral load is brought down, and the question is revisited. The delay is usually short and it is a safety measure, not a refusal.
- A liver or other solid-organ transplant — checkpoint inhibitors release the same immune brakes that stop a transplanted organ being rejected. Rejection in this setting can be severe and sometimes irreversible. Any decision is taken jointly with the transplant team, and is often against.
- Autoimmune liver disease, or autoimmune disease needing ongoing high-dose immune suppression — the risk of a serious flare rises, and the immune suppression itself works against the treatment. This is weighed individually rather than ruled out by reflex.
- Lower-GI cancer reported as MSS or pMMR — about 95 in every 100 metastatic colorectal cancers. Checkpoint inhibitor immunotherapy alone is not an evidence-based option here, whatever the hepatitis or liver status. Chemotherapy, targeted therapy chosen on other molecular results, and clinical trials remain the established path.
Being told no today is not always never. A viral load that comes down, or liver function that recovers after the cirrhosis is managed, can change the answer. Ask what would need to change and by when.
Answers before decisions
Know Whether Your Liver Can Safely Carry This Treatment
Yes or no, you deserve to hear it plainly, with the reason named and the alternatives set out. A medical oncologist will go through your reports with you.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Immunotherapy With Hepatitis B or Cirrhosis — Your Questions Answered
Is immunotherapy safe if you have hepatitis B or cirrhosis?
For most patients with liver or lower-GI cancer in India, immunotherapy is not an option in the first place, so eligibility is settled before safety is. Among those for whom it is an option, chronic hepatitis B or well-compensated cirrhosis is usually not a bar on its own. The virus is suppressed with antiviral tablets first, liver function is graded, and liver enzymes are watched at every cycle. Decompensated cirrhosis is the point at which most teams stop, because the liver has little reserve left to absorb an immune-related reaction. The decision is made jointly by a medical oncologist and a hepatologist, on your own reports.
What is the risk of hepatitis B reactivating during immunotherapy?
Reactivation means a quiet hepatitis B infection becoming active again. With checkpoint inhibitor immunotherapy alone it is reported as uncommon. The larger risk comes later, from the steroids or other immune-suppressing medicines sometimes needed to treat an immune-related side effect. Patients who are HBsAg positive carry the higher risk. Patients who are anti-HBc positive but HBsAg negative, meaning a past infection that resolved, carry a lower but genuine risk. ASCO and NCCN guidance current as of August 2026 advise screening every patient before anticancer treatment and starting antiviral cover where the result calls for it. Cover is planned before the first cycle, not started after a problem appears.
What screening comes first before immunotherapy if you have hepatitis B or cirrhosis?
A hepatitis B panel of HBsAg, anti-HBc and anti-HBs, plus a hepatitis C antibody test. If any hepatitis B marker is positive, an HBV DNA viral load is added. Liver function is then assessed with bilirubin, albumin and INR, along with a check for fluid in the abdomen and for confusion, which together give a Child-Pugh grade. Imaging and sometimes liver stiffness measurement assess the degree of scarring. Baseline thyroid, kidney, blood count and liver enzyme values are recorded so that later changes can be recognised as immune-related rather than guessed at. This panel is standing protocol for every patient starting immunotherapy. It is not a comment on your history.
Can I have immunotherapy if my cirrhosis is Child-Pugh B or C?
Usually not in Child-Pugh C, and only case by case in early Child-Pugh B. Child-Pugh grades how much working liver you still have. Class A means the liver is compensated. Class C means it is failing. Most of the published evidence for checkpoint inhibitor immunotherapy was generated in patients with Class A liver function, so applying it to a failing liver means acting beyond what the evidence covers. In decompensated cirrhosis an immune-related liver reaction has very little reserve to act against. Where treatment is declined on these grounds, liver-directed treatment, management of the cirrhosis itself and supportive care become the priority, and the reasoning should be given to you in writing.
How do doctors tell immune hepatitis apart from a hepatitis B flare?
By the viral load, mainly. Both can raise liver enzymes and both can cause tiredness, dark urine or yellowing of the eyes, so the symptoms alone do not separate them. In immune-related hepatitis the liver enzymes rise while the HBV DNA viral load stays undetectable. In a hepatitis B reactivation flare the enzymes rise alongside a rising HBV DNA. That is why a baseline viral load taken before treatment matters so much, because there is something to compare against. The two are treated in opposite directions, one with immune suppression and one with antiviral treatment, so the distinction is not academic. Report new tiredness, dark urine or yellow eyes the same day rather than waiting for the next cycle.
I have had a liver transplant. Can I still have immunotherapy?
This is one of the few situations where the answer is usually no, and the reason is specific. Checkpoint inhibitor immunotherapy works by releasing brakes on the immune system, and those same brakes are part of what stops a transplanted organ being rejected. Rejection of a transplanted liver in this setting can be severe and is sometimes irreversible. Any decision is made jointly with the transplant team, weighed against the alternatives, and the risk is discussed openly with you and your family before anything is agreed. The same caution applies to kidney and other solid-organ transplants. Being told no here is a considered position, not a refusal to treat.
This page is general patient-education information, not a substitute for the written guidance an oncology team and a hepatologist give based on your own hepatitis serology, viral load, liver function grade and pathology report.